← All China Sxt Pharmaceuticals, INC filings

China Sxt Pharmaceuticals, INC 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
SXTC
China Sxt Pharmaceuticals, INC
20-F: SXT Pharmaceuticals Reports Significant Revenue Decline
China SXT Pharmaceuticals, Inc. announced a 35% revenue decrease for the fiscal year ended March 31, 2026, with net losses widening by 88%.
NASDAQ
SXTC
China Sxt Pharmaceuticals, INC
20-F: China SXT Pharmaceuticals Reports Widening Losses Amid Revenue Decline and Internal Control Deficiencies
China SXT Pharmaceuticals, Inc. reported a 10% revenue decrease and a 7% increase in net loss for the fiscal year ended March 31, 2025, alongside disclosed material weaknesses in its internal financial reporting controls.
NASDAQ
SXTC
China Sxt Pharmaceuticals, INC
20-F: China SXT Pharmaceuticals Reports Fiscal Year 2024 Results Amidst Regulatory Scrutiny
China SXT Pharmaceuticals reports a decrease in revenue but a significant reduction in net loss for the fiscal year ended March 31, 2024, while navigating complex regulatory landscapes in China and the U.S.